Mechanistic medicine: Novel strategies for clinical trials

References

• Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of Rituximab in autoimmune diseases. Int Immunopharmacol. 2009; 9:10–25.
   PubMed Web of Science ®Google Scholar
• Crews S, Griffin J, Huang H, Calame K, Hood L. A single VH gene segment encodes the immune response to phosphorylcholine: Somatic mutation is correlated with the class of the antibody. Cell. 1981; 25:59–66.
   PubMed Web of Science ®Google Scholar
• Kumar V, Tabibiazar R, Geysen HM, Sercarz E. Immunodominant framework region 3 peptide from TCR V beta 8.2 chain controls murine experimental autoimmune encephalomyelitis. J Immunol. 1995; 154:1941–1950.
   PubMed Web of Science ®Google Scholar
• Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, Sanz I. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B-cell tolerance. J Clin Invest. 2001; 108:1061–1070.
   PubMed Web of Science ®Google Scholar
• Cappione AJ, Pugh-Bernard AE, Anolik JH, Sanz I. Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes. J Immunol. 2004; 172:4298–4307.
   PubMed Web of Science ®Google Scholar
• Cappione A3rd, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, Sanz I. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest. 2005; 115:3205–3216.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New Engl J Med. 1999; 340:253–259.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. New Engl J Med. 2000; 343:1594–1602.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 2006; 65:753–759.
   PubMed Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W, Belimumab study group. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (B-LyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10:R109.
   Web of Science ®Google Scholar
• Cancro MP, D'Cruz DP, Khamashta MA. The role of B-lymphocyte stimulator (B-LyS) in systemic lupus erythematosus. J Clin Invest. 2009; 119:1066–1073.
   PubMed Web of Science ®Google Scholar
• Zekavat G, Rostami SY, Badkerhanian A, Parsons RF, Koeberlein B, Yu M, Ward CD, Migone TS, Yu L, Eisenbarth GS, Cancro MP, Naji A, Noorchashm H. In vivo B-LyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J Immunol. 2008; 181:8133–8144.
   PubMed Web of Science ®Google Scholar
• Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, Mackay F. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000; 192 10: 1453–1466.
   PubMed Web of Science ®Google Scholar
• Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, Cyster JG. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity. 2004; 20 4: 441–453.
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004; 20:785–798.
   PubMed Web of Science ®Google Scholar
• Zarkhin V, Li L, Sarwal MM. BAFF may modulate the rate of B-cell repopulation after Rituximab therapy for acute renal transplant rejection. Transplantation. 2009; 88:1229–1230.
   PubMed Web of Science ®Google Scholar
• Nagel A, Podstawa E, Eickmann M, Müller HH, Hertl M, Eming R. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in Pe. vulgaris. J Invest Dermatol. 2009; 129:2202–2210.
   PubMed Web of Science ®Google Scholar
• West K. CP-690550, a Jak3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Invest Drugs. 2009; 10:491–504.
   PubMed Web of Science ®Google Scholar
• Borie DC, O'Shea JJ, Changelian PS. Jak3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med. 2004; 10:532–541.
   PubMed Web of Science ®Google Scholar
• Quaedackers ME, Mol W, Korevaar SS, van Gurp EA, van Ijcken WF, Chan G, Weimar W, Baan CC. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the Jak/STAT pathway in kidney transplant patients. Transplantation. 2009; 88 8: 1002–1009.
   PubMed Web of Science ®Google Scholar
• Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the Jak2V617F mutation. Cancer Sci. 2008; 99:1265–1273.
   PubMed Web of Science ®Google Scholar
• Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol. 2000; 12:557–562.
   PubMed Web of Science ®Google Scholar
• Hirano T. Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. Int Immunopharmacol. 2007; 7:3–22.
   PubMed Web of Science ®Google Scholar
• Eming R, Büdinger L, Riechers R, Christensen O, Bohlen H, Kalish R, Hertl M. Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and Pe vulgaris by enzyme-linked immunospot assay. Br J Dermatol. 2000; 143:1279–1282.
   PubMed Web of Science ®Google Scholar
• Yamagami J, Takahashi H, Ota T, Amagai M. Genetic characterization of human Dsg3-specific B cells isolated by flow cytometry from the peripheral blood of patients with Pe. vulgaris. J Dermatol Sci. 2008; 52:98–107.
   PubMed Web of Science ®Google Scholar
• Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in Pe. vulgaris. J Invest Dermatol. 2008; 128:2850–2858.
   PubMed Web of Science ®Google Scholar
• Metz DP, Mohn D, Zhang M, Horan T, Kim H, Deshpande R, Jacobsen F, Shen WD, Zhang L, Doellgast G, Narayanan A, Dalphin M, Kuchimanchi KR, Horner M, Chung J, Siu G. Defining dose–response relationships in the therapeutic blockade of B7RP-1-dependent immune responses. Eur J Pharmacol. 2009; 610:110–118.
   PubMed Web of Science ®Google Scholar
• Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999; 103:1243–1252.
   PubMed Web of Science ®Google Scholar
• Mathis D, Benoist C. AIRE. Ann Rev Immunol. 2009; 27:287–312.
   PubMed Web of Science ®Google Scholar
• Su MA, Anderson MS. Monogenic autoimmune diseases: Insights into self-tolerance. Pediat Res. 2009; 65:20R–25R.
   Web of Science ®Google Scholar
• Bi LL, Pan G, Atkinson TP, Zheng L, Dale JK, Makris C, Reddy V, McDonald JM, Siegel RM, Puck JM, Lenardo MJ, Straus SE. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib. BMC Med Genet. 2007; 8:41.
   PubMed Web of Science ®Google Scholar
• Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001; 27:18–20.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27:20–21.
   PubMed Web of Science ®Google Scholar
• Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D. Projection of an immunological self shadow within the thymus by the AIRE protein. Science. 2002; 298:1395–1401.
   PubMed Web of Science ®Google Scholar
• Ramsey C, Bukrinsky A, Peltonen L. Systematic mutagenesis of the functional domains of AIRE reveals their role in intracellular targeting. Human Mol Genet. 2002; 11:3299–3308.
   PubMed Web of Science ®Google Scholar
• Devoss JJ, Shum AK, Johannes KP, Lu W, Krawisz AK, Wang P, Yang T, Leclair NP, Austin C, Strauss EC, Anderson MS. Effector mechanisms of the autoimmune syndrome in the murine model of autoimmune polyglandular syndrome type 1. J Immunol. 2008; 181:4072–4079.
   PubMed Web of Science ®Google Scholar
• Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheumat. 1993; 36:1305–1314.
   PubMed Web of Science ®Google Scholar
• van den Berg WB, Joosten LA, Helsen M, van de Loo FA. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exper Immun. 1994; 95:237–243.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004; 63:1062–1068.
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle–Wells syndrome and response to anakinra. Arthritis Rheumat. 2004; 50:607–612.
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005; 201:1479–1486.
   PubMed Web of Science ®Google Scholar
• Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, Ardura M, Chung W, Smith E, Wise C, Palucka K, Ramilo O, Punaro M, Banchereau J, Pascual V. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med. 2007; 204:2131–2144.
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P. International league of associations for rheumatology. International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol. 2004; 31:390–392.
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Patel P, Palucka AK, Chaussabel D, Banchereau J. How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev. 2008; 223:39–59.
   PubMed Web of Science ®Google Scholar
• Amel-Kashipaz MR, Huggins ML, Lanyon P, Robins A, Todd I, Powell RJ. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the Jak/STAT pathway in kidney transplant patients. J Autoimmun. 2001; 17:155–163.
   PubMedGoogle Scholar
• Bonelli M, Savitskaya A, von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, Scheinecker C. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol. 2008; 20:861–868.
   PubMed Web of Science ®Google Scholar
• Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM, CD69 HLA-DR. and the IL-2R identify persistently activated T cells in Ps vulgaris lesional skin: Blood and skin comparisons by flow cytometry. J Autoimmun. 2000; 14:63–78.
   PubMed Web of Science ®Google Scholar
• De Miguel S, Jover JA, Vadillo C, Judez E, Loza E, Fernandez-Gutierrez B. B cell activation in rheumatoid arthritis patients under Infliximab treatment. Clin Exp Rheumatol. 2003; 21:726–732.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Yamaguchi K, Tanaka T, Mizuno Y, Hijikata A, Ohara O, Takada H, Kusuhara K, Hara T. Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease. Clin Exp Immunol. 2010; 160:246–255.
   PubMed Web of Science ®Google Scholar
• Al-Shukaili A, Al-Kaabi J, Hassan B. A comparative study of interleukin-1β production and p2 × 7 expression after ATP stimulation by peripheral blood mononuclear cells isolated from rheumatoid arthritis patients and normal healthy controls. Inflammation. 2008; 31:84–90.
   PubMed Web of Science ®Google Scholar
• Ráki M, Fallang LE, Brottveit M, Bergseng E, Quarsten H, Lundin KE, Sollid LM. Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of celiac disease patients. Proc Natl Acad Sci USA. 2007; 104:2831–2836.
   PubMed Web of Science ®Google Scholar
• Ling P, Ngo K, Nguyen S, Thurmond RL, Edwards JP, Karlsson L, Fung-Leung WP. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol. 2004; 142:161–171.
   PubMed Web of Science ®Google Scholar
• Chirumbolo S, Conforti A, Ortolani R, Vella A, Marzotto M, Bellavite P. Stimulus-specific regulation of CD63 and CD203c membrane expression in human basophils by the flavonoid quercetin. Int Immunopharmacol. 2010; 10:183–192.
   PubMed Web of Science ®Google Scholar
• Zoog SJ, Itano A, Trueblood E, Pacheco E, Zhou L, Zhang X, Ferbas J, Ng GY, Juan G. Antagonists of CD117 (cKit) signaling inhibit mast cell accumulation in healing skin wounds. Cytometry A. 2009; 75:189–198.
   PubMedGoogle Scholar
• Johnson C, Walls RS, Ruwoldt A. Delayed hypersensitivity to tetanus toxoid in man: In vivo and in vitro studies. Pathology. 1983; 15:369–372.
   PubMed Web of Science ®Google Scholar